Evidence map›Paper›PMID 40422227›Full record

ReviewCells2025

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now.

Alessandro Cuttone, Anastasia Xourafa, Carmela Morace, Vittorio Cannavò, Francesca Maria Bueti, Giuseppe Mandraffino, Giovanni Squadrito, Giorgio Basile, Agostino Gaudio, Antonino Catalano and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandro CuttoneUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.ORCID 0000-0003-2842-1088
Anastasia XourafaUnit of Thalassemia, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.ORCID 0000-0001-5126-0927
Carmela MoraceUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.
Vittorio CannavòUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.ORCID 0009-0007-4903-055X
Francesca Maria BuetiUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.ORCID 0000-0002-3647-5628
Giuseppe MandraffinoUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.ORCID 0000-0003-0272-2237
Giovanni SquadritoUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.
Giorgio BasileUnit of Geriatrics, Department of Biomedical and Dental Science and Morphofunctional Imaging, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.
Agostino GaudioUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", 95123 Catania, Italy.ORCID 0000-0002-9958-9606
Antonino CatalanoUnit of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.ORCID 0000-0003-3890-2299
Giuseppina Tiziana RussoUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.
Federica BelloneUnit of Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital G. Martino, University of Messina, 98100 Messina, Italy.ORCID 0000-0002-0467-4921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus has been knowingly associated with increased risk of fractures, so much so that skeletal fragility is considered a complication of diabetes. Determinants of bone fragility in this chronic condition are several, and the diabetes treatment choice could influence bone metabolism. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently expanded the therapeutic armamentarium for type 2 diabetes mellitus (T2D); these antihyperglycemic drugs act by reducing renal glucose reabsorption in the proximal tubule and have a proven cardiorenal benefit. The role of SGLT2i towards phospho-calcium metabolism is still unclear, so we aimed to review the current evidence of the relationship between SGLT2i and calcium and phosphate homeostasis. The PubMed, Scopus, and Web of Knowledge databases were searched to identify original research articles, meta-analyses, and scientific reviews on effects on bone metabolism in T2D patients treated with SGLT2i. Emerging data indicate that SGLT2i may lead to a rise of bone turnover markers, promoting a lower skeletal bone density and an increased fracture risk on murine models, but in real-world studies, results are controversial. Therefore, more clinical trials are needed to further clarify this topic, and the effects of SGLT2i on calcium homeostasis remain to date poorly understood.

Indexed as

CalciumDiabetes Mellitus, Type 2HomeostasisSodium-Glucose Transporter 2 InhibitorsAnimalsHumansCalciumSodium-Glucose Transporter 2 Inhibitorsbone fragilitycalcium metabolismcanagliflozindapagliflozindiabetes mellitusempagliflozinertugliflozinFGF-23parathyroid hormoneSGLT2 inhibitors

Identifiers

PMID40422227
PMCPMC12110041

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.